ArticleFrontiers in oncology2025
Patent landscape of nanotechnology - based nucleic acid delivery systems for breast cancer therapies.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is the most prevalent malignancy among women worldwide and remains a major public health concern. Conventional treatments are often limited by adverse effects and resistance. Nucleic acid-based gene therapies, supported by nanoparticle delivery systems, offer target and efficient therapeutic alternatives. The growing number of related patents about nanotechnology-based nucleic acid delivery systems for breast cancer treatment highlights the importance of understanding this landscape to advance research and innovation. Therefore, this study aimed to analyze the global patent landscape related to nanotechnology-based delivery systems for nucleic acid therapies in breast cancer, highlighting key technological platforms, emerging trends, and opportunities for research and development. Methodology: A patent landscape analysis was conducted using the Derwent World Patents Index (DWPI, Clarivate Analytics). The search strategy combined keywords and International Patent Classification (IPC) codes related to breast cancer, nucleic acid therapies, and delivery platforms. A total of 1,084 patent families were identified. Filters were applied to classify documents as alive, dead, or indeterminate, focusing on active patents from the past five years (2020-2025), resulting in 323 patents selected for details examination. Results: The analysis revealed a substantial increase in patent filings over the past decade, with the United States, China, and Europe leading technological innovations. Lipid-based nanoparticles and polymeric carriers were the most frequently cited platforms. The patents showed a strong focus on targeted delivery strategies, combinatorial approaches, and RNA interference technologies. Discussion: The findings highlight the transformative potential of nanotechnology for nucleic acid therapies in breast cancer. Despite manufacturing and regulatory challenges, the patent landscape demonstrates a dynamic and competitive field. Mapping technological developments provides valuable insights to guide strategic decisions in research and development and to identify underexplored areas with high innovation potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.